News From The Journal Of Clinical Investigation: Jan. 9, 2012
ONCOLOGY: KRAS provides maintenance for pancreatic cancer The outlook for individuals diagnosed with the most common form of pancreatic cancer, pancreatic ductal adenocarcinoma (PDA), is very poor; the average time of survival after diagnosis is less than 6 months. New therapeutic approaches are therefore much needed…
(more...)
